Delta-Like Ligand 3 (DLL3) is a promising target in small cell lung cancer

Tarlatamab - Bi-specific T cell engager (BiTE®) (NCT03392064)

Median duration of response: 13 months

Borghaei H, WCLC 2022
DLL3 is highly expressed in neuroendocrine subtypes of SCLC

DLL3 gene expression in SCLC patient samples

DLL3 surface expression in SCLC by subtypes
DLL3-targeting CAR T showed robust in-vitro cytotoxicity against SCLC

![Diagram showing DLL3-CAR T components and activity](image)

### DLL3 CAR T in vitro activity (E:T 1:1)

- **H82**
  - DLL3 high
  - % cell viability

- **H841**
  - DLL3 low
  - % cell viability

### Graphs showing cell viability for H82 and H841 cell lines with and without DLL3 CAR T treatment.